Psychiatric and Psychological Issues



Breast cancer is inherently stressful. Every person diagnosed with the disease immediately experiences understandable fear of dying of cancer, despite the fact that half of all breast cancer patients will live to die of something else. They also fear disfigurement, despite the increasing prevalence of breast-sparing treatments such as lumpectomy and radiation. These concerns tend to isolate them from social support, since such fundamental concerns arouse anxiety in others as well, and may lead to avoidance on both sides. Cancer treatments can induce nausea, fatigue, burns, lymphedema, disfigurement, and pain. The illness and its treatment cause acute disruption of educational, vocational, and social roles. Thus, it is natural that breast cancer patients experience stress, distress, anxiety, and depression. Few people are well prepared by life for the multiple existential problems that come with a diagnosis of breast cancer. Recognizing that these issues are always part of returning a patient to a well-state allows the clinician to better support patients and enables the astute clinician to recognize the potential need for consultation from a psychologist or psychiatrist.


Breast Cancer Breast Cancer Patient Posttraumatic Stress Disorder Primary Negative Gamma Amino Butyric Acid 


  1. 1.
    Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res. 1998;45(3):215–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Rodin G, Voshart K. Depression in the medically ill: an overview. Am J Psychiatry. 1986;143(6): 696–705.PubMedGoogle Scholar
  3. 3.
    Spiegel D. Cancer and depression. Br J Psychiatry. 1996;168 Suppl 30:109–16.Google Scholar
  4. 4.
    McDaniel JS, Musselman DL, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52(2):89–99.PubMedCrossRefGoogle Scholar
  5. 5.
    Koopman C, Butler LD, et al. Traumatic stress symptoms among women with recently ­diagnosed primary breast cancer. J Trauma Stress. 2002;15(4):277–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Derogatis LR, Morrow GR, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249(6):751–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Katon W, Sullivan M. Depression and chronic medical illness. J Behav Med. 1990;2010:3–2010.Google Scholar
  8. 8.
    Weitzner MA, Meyers CA, et al. Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer. 1997;5(3):241–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen L, de Moor C, et al. The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial. Cancer. 2001; 91(10):1949–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Spiegel D, Bloom JR, et al. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry. 1981;38(5):527–33.PubMedCrossRefGoogle Scholar
  11. 2010.
    Bukberg J, Penman D, et al. Depression in hospitalized cancer patients. Psychosom Med. 1984;46:199–212.PubMedGoogle Scholar
  12. 12.
    Spiegel D, Sands S, et al. Pain and depression in patients with cancer. Cancer. 1994;74(9): 2570–8.PubMedCrossRefGoogle Scholar
  13. 13.
    van’t Spijker A, Trijsburg RW, et al. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med. 1997;59(3):280–93.PubMedGoogle Scholar
  14. 14.
    Wellisch D, Carr C. Psychosocial outcomes of breast cancer therapies: lumpectomy vs mastectomy. Psychosomatics. 1991;32(2):177–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Pozo C, Carver CS, et al. Effects of mastectomy versus lumpectomy on emotional adjustment to breast cancer: a prospective study of the first year postsurgery. J Clin Oncol. 1992;10(8): 1292–8.PubMedGoogle Scholar
  16. 16.
    Levy SM, Haynes LT, et al. Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up [see comments]. Health Psychol. 1992;2010(6):349–54.CrossRefGoogle Scholar
  17. 17.
    Peto R, Boreham J, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355(9217):1822.PubMedCrossRefGoogle Scholar
  18. 18.
    Spiegel D. Mind matters – group therapy and survival in breast cancer. [letter; comment.]. N Engl J Med. 2001;345(24):1767–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Han WT, Collie K, et al. Breast cancer and problems with medical interactions: relationships with traumatic stress, emotional self-efficacy, and social support. Psychooncology. 2005;14(4): 318–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Pirl WF, Roth AJ. Oncology (Huntingt). 1999;13(9):1293–301. discussion 1301-2, 1305-6.Google Scholar
  21. 21.
    Lerman C, Kash K, et al. Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr. 1994;16: 171–6.PubMedGoogle Scholar
  22. 22.
    Richardson JL, Shelton DR, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8(2):356–64.PubMedGoogle Scholar
  23. 23.
    Ayres A, Hoon PW, et al. Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patients. J Psychosom Res. 1994;38(5):393–402.PubMedCrossRefGoogle Scholar
  24. 24.
    Eisenberg D, Davis R, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA. 1997;280:1569–75.CrossRefGoogle Scholar
  25. 25.
    Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer. 2000;88(3):615–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sollner W, Zingg-Schir M, et al. Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma [see comments]. Arch Dermatol. 1997;133(3):316–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54(3):269–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun. 2003;17(5):321–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Sephton SE, Sapolsky RM, et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000.PubMedCrossRefGoogle Scholar
  30. 30.
    Editorial. Hypnosis may lower costs of breast surgery. CA Cancer J Clin. 2008;58:3–4.Google Scholar
  31. 31.
    Lang EV, Berbaum KS, et al. Adjunctive self-hypnotic relaxation for outpatient medical ­procedures: a prospective randomized trial with women undergoing large core breast biopsy. Pain. 2006;126(1–3):155–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Montgomery GH, Bovbjerg DH, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst. 2007;99(17): 1304–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Spiegel H, Spiegel D. Trance and treatment: clinical uses of hypnosis. Washington D.C.: American Psychiatric Publishing; 2004.Google Scholar
  34. 34.
    Faymonville ME, Laureys S, et al. Neural mechanisms of antinociceptive effects of hypnosis. Anesthesiology. 2000;92(5):1257–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Rainville P, Duncan GH, et al. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science. 1997;277:968–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Rainville P, Hofbauer RK, et al. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. J Cogn Neurosci. 2002;14(6):887–901.PubMedCrossRefGoogle Scholar
  37. 37.
    Spiegel D, Bierre P, et al. Hypnotic alteration of somatosensory perception. Am J Psychiatry. 1989;146(6):749–54.PubMedGoogle Scholar
  38. 38.
    Kosslyn SM, Thompson WL, et al. Hypnotic visual illusion alters color processing in the brain. Am J Psychiatry. 2000;157(8):1279–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Lang E, Benotsch E, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet. 2000;355:1486–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Lang E, Joyce J. Self-hypnotic relaxation during interventional radiological procedures: effects on pain perception and intravenous drug use. Int J Clin Exp Hypn. 1996;XLIV(2):106–19.CrossRefGoogle Scholar
  41. 41.
    Lang EV, Rosen MP. Cost analysis of adjunct hypnosis with sedation during outpatient interventional radiologic procedures. Radiology. 2002;222(2):375–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Kabat-Zinn J, Massion AO, et al. Meditation. In: Holland JC, editor. Psychooncology. New York: Oxford University Press; 1998. p. 767–79.Google Scholar
  43. 43.
    Spiegel D. A 43-year-old woman coping with cancer [clinical conference] [see comments]. JAMA. 1999;282(4):371–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Spiegel D, Classen C. Group therapy for cancer patients: a research-based handbook of psychosocial care. New York: Basic Books; 2000.Google Scholar
  45. 45.
    Yalom ID. Existential psychotherapy. New York: Basic Books; 1980.Google Scholar
  46. 46.
    Spiegel D, Morrow GR, et al. Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study. Psychooncology. 1999;8(6):482–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Spiegel D. Mind matters: effects of group support on cancer patients. J NIH Res. 1991;3:61–3.Google Scholar
  48. 48.
    Giese-Davis J, DiMiceli S, et al. Emotional expression and diurnal cortisol slope in women with metastatic breast cancer in supportive-expressive group therapy: a preliminary study. Biol Psychol. 2006;73(2):190–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Goodwin PJ et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345(24):1719–26.PubMedCrossRefGoogle Scholar
  50. 50.
    Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med. 1983;45(4):333–9.PubMedGoogle Scholar
  51. 51.
    Classen C, Butler LD, et al. Supportive-expressive group therapy reduces distress in metastatic breast cancer patients: a randomized clinical intervention trial. Arch Gen Psychiatry. 2001;58: 494–501.PubMedCrossRefGoogle Scholar
  52. 52.
    Cain EN, Kohorn EI, et al. Psychosocial benefits of a cancer support group. Cancer. 1986; 57(1):183–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Spiegel D, Bloom JR. Pain in metastatic breast cancer. Cancer. 1983;52(2):341–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Giese-Davis J, Koopman C, et al. Change in emotion-regulation strategy for women with metastatic breast cancer following supportive-expressive group therapy. J Consult Clin Psychol. 2002;70(4):916–25.PubMedCrossRefGoogle Scholar
  55. 55.
    Kelly CM, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Bmj. 2010;340: p. c693.Google Scholar
  56. 56.
    Lash TL, et al, Tamoxifen’s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer, 2008;99(4): p. 616–21.Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral Sciences, Stanford Center for Integrative MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations